Newton, Massachusetts – January 3, 2008
NeuroHealing Pharmaceuticals, a private, clinical stage company developing drug treatments for individuals with neuro-rehabilitation needs, today announced the appointment of Burt A. Adelman, M.D., to the company’s Board of Directors. Burt Adelman M.D. was most recently Executive Vice President, Portfolio Strategy at Biogen Idec, having retired from this position on December 31, 2007. Previously, Dr. Adelman held the position of Executive Vice President, Development since the merger of Biogen, Inc and Idec in 2003. Dr. Adelman was previously Executive Vice President, Research & Development, and Vice President of Medical Research at Biogen, Inc. He began his career with Biogen in 1991, as Director of Medical Research, and held positions of increasing responsibility including VP, Regulatory Affairs, and VP, Development Operations. In that role he oversaw the Preclinical Development, Medical Operations and Regulatory Affairs groups. Dr. Adelman has served as a lecturer in medicine at the Harvard Medical School, Associate Professor of Medicine at the Medical College of Virginia, and as Chief of Hematology service at the Hunter Holmes McGuire VA Medical Center. He received his M.D. from Cornell Medical College. He is a member of the Board of Directors for the New England Healthcare Institute and the New England Division of the American Cancer Society. “We are very pleased to welcome Dr. Adelman to our Board. Burt is a highly respected physician, scientist, educator and business leader, and brings unparalleled expertise in drug development, clinical trials and strategic alliances. As director of medical research at Biogen, he led the development and regulatory efforts for four currently marketed drugs, and rose through several leadership positions. His involvement and guidance will be invaluable as NeuroHealing’s compounds advance through clinical trials and we continue to pursue our product development and partnering goals,” commented Neal M. Farber, Ph.D., CEO of NeuroHealing. “NeuroHealing is an exciting company that has great potential to make an impact on the lives of patients with brain injuries,” stated Dr. Adelman. “I am impressed by the significance of the clinical data and by the progress that NeuroHealing has made to date with streamline resources.”
About NeuroHealing Pharmaceuticals
NeuroHealing Pharmaceuticals, Inc. is a clinical stage private company developing therapies to improve the neuro-rehabilitation process and functional outcome for patients who have suffered debilitating injuries to the central nervous system. Clinical stage programs include: NH001 (phase II), a dopaminergic agent to help post traumatic brain injury patients to emerge from a coma, vegetative or minimally consciousness state; NH004 (phase II), an anticholinergic agent in a convenient intra-orally muco-adhesive dissolving film to help treat motor neuron disease patients who suffer from sialorrhea (drooling); and NH02D, a novel mechanism compound to accelerate the rehabilitation outcomes of stroke patients who remain with chronic motor and cognitive disabilities.